Cryo-Cell International, Inc. (CCEL)
NYSEAMERICAN: CCEL · IEX Real-Time Price · USD
7.45
-0.27 (-3.50%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Cryo-Cell International Income Statement
Financials in millions USD. Fiscal year is December - November.
Millions USD. Fiscal year is Dec - Nov.
Year Ending | TTM | Nov 30, 2023 | Nov 30, 2022 | Nov 30, 2021 | Nov 30, 2020 | Nov 30, 2019 | 2018 - 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 31.64 | 31.34 | 30.34 | 28.88 | 31.15 | 31.82 | Upgrade
|
| Revenue Growth (YoY) | 1.93% | 3.32% | 5.03% | -7.26% | -2.10% | 8.89% | Upgrade
|
| Cost of Revenue | 12.15 | 12.18 | 8.79 | 10.15 | 10.94 | 12.37 | Upgrade
|
| Gross Profit | 19.49 | 19.16 | 21.54 | 18.73 | 20.21 | 19.45 | Upgrade
|
| Selling, General & Admin | 17.56 | 17.12 | 15.58 | 14.61 | 14.29 | 14.89 | Upgrade
|
| Research & Development | 1.53 | 1.17 | 0.38 | 0.05 | 0.02 | 0.03 | Upgrade
|
| Depreciation & Amortization | 0.66 | 1.12 | 1.12 | 0.83 | 0.17 | 0.21 | Upgrade
|
| Operating Expenses | 19.75 | 19.41 | 17.08 | 15.49 | 14.48 | 15.13 | Upgrade
|
| Operating Income | -0.26 | -0.25 | 4.46 | 3.24 | 5.72 | 4.32 | Upgrade
|
| Interest Expense | -0.43 | -1.11 | -1.08 | -1.38 | -1.54 | -1.7 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -0.69 | -1.36 | 3.39 | 1.86 | 4.18 | 2.62 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.27 | 0.05 | -0.04 | -0.01 | -0.01 | 0.03 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.41 | -0.02 | - | - | Upgrade
|
| Asset Writedown | -13.11 | -13.11 | - | - | - | - | Upgrade
|
| Other Unusual Items | 0.87 | 1.05 | -0.44 | 0.78 | 0.87 | 0.74 | Upgrade
|
| Pretax Income | -12.66 | -13.36 | 3.32 | 2.61 | 5.04 | 3.39 | Upgrade
|
| Income Tax Expense | -3.36 | -3.84 | 0.55 | 0.53 | 1.41 | 1.1 | Upgrade
|
| Net Income | -9.3 | -9.52 | 2.77 | 2.08 | 3.62 | 2.29 | Upgrade
|
| Net Income to Common | -9.3 | -9.52 | 2.77 | 2.08 | 3.62 | 2.29 | Upgrade
|
| Net Income Growth | - | - | 33.02% | -42.52% | 58.23% | - | Upgrade
|
| Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 8 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 8 | 8 | Upgrade
|
| Shares Change (YoY) | -2.16% | -1.69% | 1.46% | 2.72% | -3.24% | 12.72% | Upgrade
|
| EPS (Basic) | -1.13 | -1.14 | 0.33 | 0.26 | 0.48 | 0.29 | Upgrade
|
| EPS (Diluted) | -1.13 | -1.14 | 0.33 | 0.25 | 0.45 | 0.27 | Upgrade
|
| EPS Growth | - | - | 30.95% | -44.44% | 66.67% | - | Upgrade
|
| Free Cash Flow | -0.51 | 2.08 | -3.6 | 6.09 | 8.37 | 5.63 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | 0.25 | -0.42 | 0.73 | 1.03 | 0.67 | Upgrade
|
| Gross Margin | 61.59% | 61.14% | 71.02% | 64.85% | 64.87% | 61.12% | Upgrade
|
| Operating Margin | -0.82% | -0.79% | 14.70% | 11.20% | 18.37% | 13.58% | Upgrade
|
| Profit Margin | -29.38% | -30.38% | 9.14% | 7.21% | 11.64% | 7.20% | Upgrade
|
| Free Cash Flow Margin | -1.62% | 6.64% | -11.85% | 21.09% | 26.86% | 17.70% | Upgrade
|
| EBITDA | 0.61 | 1.15 | 5.96 | 4.27 | 6.09 | 4.72 | Upgrade
|
| EBITDA Margin | 1.94% | 3.68% | 19.64% | 14.80% | 19.56% | 14.84% | Upgrade
|
| D&A For EBITDA | 0.87 | 1.4 | 1.5 | 1.04 | 0.37 | 0.4 | Upgrade
|
| EBIT | -0.26 | -0.25 | 4.46 | 3.24 | 5.72 | 4.32 | Upgrade
|
| EBIT Margin | -0.82% | -0.79% | 14.70% | 11.20% | 18.37% | 13.58% | Upgrade
|
| Effective Tax Rate | - | - | 16.50% | 20.21% | 28.07% | 32.45% | Upgrade
|
| Revenue as Reported | 31.64 | 31.34 | 30.34 | 28.88 | 31.15 | 31.82 | Upgrade
|
| Advertising Expenses | - | 0.95 | 0.76 | 0.84 | 0.85 | 0.98 | Upgrade
|
Source: S&P Capital IQ. Standard template.